PT  - JOURNAL ARTICLE
AU  - Moreira, João Manoel Losada
TI  - Control dynamics of the COVID-19 pandemic in China and South Korea
AID  - 10.1101/2020.05.01.20087650
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.05.01.20087650
4099  - http://medrxiv.org/content/early/2020/05/06/2020.05.01.20087650.short
4100  - http://medrxiv.org/content/early/2020/05/06/2020.05.01.20087650.full
AB  - Social isolation measures reduce the population’s infection rate with the COVID-19 virus, but its effectiveness is difficult to quantify. The successful control of the pandemic carried out by China and South Korea is studied using a scheme based on the net relative rate of infection which is very sensitive to sudden changes in the epidemic evolution. The net relative rate of infection for China and South Korea without containment measures, that is, with free proliferation of the virus, lies between 10 and 40 %/day or doubling times of infected persons between 3.5 and 2 days. After measures of containment it dropped and stabilized. South Korea stabilized it around 1 %/day and China around 0.05 %/day with doubling times of 70 days and 1400 days, respectively. A discussion is provided about their processes of control and stabilization of the epidemic process and about the scheme used to study them.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe author thanks the Brazilian agency Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) for financial support and acknowledges it had no interference on data collection, interpretation, or decision to submit the work for publication.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data utilized in the manuscript are available.